Heme arginate + L-arginine — Competitive Intelligence Brief

Heme arginate + L-arginine (Heme arginate + L-arginine) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Heme replacement therapy with nitric oxide donor. Area: Metabolic/Genetic disorders.

marketed Heme replacement therapy with nitric oxide donor ALA synthase (indirect inhibition via heme feedback); nitric oxide synthase (L-arginine substrate) Metabolic/Genetic disorders Small molecule

Target snapshot

Heme arginate + L-arginine (Heme arginate + L-arginine) — Radboud University Medical Center. Heme arginate replenishes depleted heme pools while L-arginine provides substrate for nitric oxide synthesis, together improving endothelial function and reducing vasoconstriction in acute porphyria crises.

Comparator set

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Heme arginate + L-arginine TARGET	Heme arginate + L-arginine	Radboud University Medical Center	marketed	Heme replacement therapy with nitric oxide donor	ALA synthase (indirect inhibition via heme feedback); nitric oxide synthase (L-arginine substrate)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Heme replacement therapy with nitric oxide donor class)

1. Radboud University Medical Center · 1 drug in this class